Third Harmonic Bio, Inc. (THRD)
- Previous Close
11.33 - Open
11.29 - Bid 10.46 x 200
- Ask 10.84 x 200
- Day's Range
10.61 - 11.29 - 52 Week Range
4.31 - 12.42 - Volume
7,321 - Avg. Volume
149,398 - Market Cap (intraday)
433.652M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.78 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.55
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
www.thirdharmonicbio.comRecent News: THRD
Performance Overview: THRD
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: THRD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: THRD
Valuation Measures
Market Cap
461.77M
Enterprise Value
196.66M
Trailing P/E
13.41
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.48
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-9.53%
Return on Equity (ttm)
-11.04%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.82M
Diluted EPS (ttm)
-0.78
Balance Sheet and Cash Flow
Total Cash (mrq)
269.07M
Total Debt/Equity (mrq)
1.47%
Levered Free Cash Flow (ttm)
-18.04M